Acha-Orbea Hans, Full Professor
Hans Acha-Orbea studied biochemistry at the ETH in Zurich and received a Ph.D. in biochemistry in 1984 with H. Hengartner, H. Zuber and R. Zinkernagel. After a postdoctoral fellowship with H. O. MacDevitt at Stanford University in California, USA he came to the Ludwig Institute of Cancer Research, Lausanne Branch as an Assistant Member and START fellow in 1989. Since 1994 he had a joint appointment as an Associate Member at the Ludwig Institute for Cancer Research and Associate Professor at the Department of Biochemistry. Since 2008 he is Full Professor at the Department of Biochemistry. The main focus of his laboratory concerns research on dendritic cells with special interests in pathogen-host interaction, immune response and immune tolerance.
TRANSGENIC MICE DEVELOPING DENDRITIC CELL TUMORS, A TOOL FOR INVESTIGATING DENDRITIC CELL IMMUNOLOGY AND A MODEL FOR HUMAN HISTIOCYTOSIS
CHARACTERIZATION OF A NEW HISTIOCYTOSIS MODEL; ONCOGENIC TRANSFORMATION OF DENDRITIC CELLS IN TRANSGENIC MICE
Dendritic cells (DC) are the key regulators of immune response and immune tolerance. In the absence of microbes and danger signals they induce immune tolerance towards presented peptides whereas after microbial infection they direct the immune response towards the infecting microbe. They can imprint the site of infection as well as the effector function required for elimination of the microbe on the responding T cells. Different subset of DC exist in mice with partly understood functions. Amongst the conventional DC the two major subsets are CD8+ and CD11b+ DC respectively. The former are more efficient at CD8 T cell priming and crosspresentation, the latter for CD4 T cell priming. Plasmacytoid DC are responsible for large amounts of type I interferon production immediately after pathogen encounter and later for antigen presentation. In addition several subsets of tissue DC such as Langerhans cells of the skin exist.
We have obtained a first model for human histiocytosis by overexpressing the SV40 large T oncogene specifically in DC using the CD11c promoter (2). Depending on the expression levels of the transgene in transgenic founders mice show DC transformation at 4 or 12 months respectively with full penetrance (Fig. 1 ). The forming tumors are all CD8+ DC and we were able to show that always mature splenic nonactivated CD8+ DC transform after about 3 months or 6-12 months in the two transgenic founder lines. The reason for this preferential transformation of CD8+ DC might lie in the higher steady state proliferation of this subset in normal mice. Despite the fact that Langerhans are thought to be at the origin of human Langerhans cell histiocytosis the non-Langerhans cell-derived CD8+ tumors in our mice show striking similarities to human disease. Tumors express high levels of Langerin as in human disease, a marker thought to be specific for Langerhans cells until recently (Fig. 1). These results raise the possibility that in a subset of human disease transformation/accumulation of conventional splenic DC might be involved. The tumors maintain most of the features of freshly isolated CD8+ DC such as cytokine production after Toll-like receptor stimulation, antigen (cross)-presentation and expression of specific transcription factors and surface markers. Stable cell lines can be easily derived from the tumors that maintain all the features of non-activated DC. These tools represent the first stable cell lines with the features of normal DC and are valuable tools for designing experiments to understand DC function.
We now can easily isolate stable, exogenous growth factor-independent DC lines from wild type, KO or transgenic mice. These lines keep all the tested features of freshly isolated CD8+ DC such as (cross)-presentation, cytokine production and upregulation of co-stimulatory molecules upon TLR stimulation. We have observed that these tumoral cell lines die by apoptosis within 40 hours after TLR stimulation. Using the cell lines we were able to quantitate pro- and anti-apoptotic molecules as well as effector caspase cleavage after activation by Western blot analysis. Similar effects were observed on wild type DC in vivo. Using KO mice for pro-apoptotic molecules we could define the pairs of pro-apoptotic molecules as well as cytokines required to induce apoptosis of wild type CD8+ DC. We also found that the cytokines produced after TLR stimulation are necessary and sufficient for induction of apoptosis in CD8+ DC (5, 6).
We are in the process of generating models with transformed Langerhans cells and CD11b+ DC. In addition, we have lentivirally transduced DC lines to produce torlerigenic molecules in order to address the mechanisms of tolerance induction by DC in vivo and in vitro, We are also addressing the role of activation-induced DC death in induction of immune response and tolerance and in protection from immune pathologies in KO mice and DC lines.
PLASMA CELL DIFFERENTIATION DURING AN IMMUNE RESPONSE
During a T cell-mediated immune response, antigen-specific B cells become activated via DC-primed antigen-specific T cells to form germinal centers and develop into memory and effector cells (plasma cells). Plasma cells migrate back to the bone marrow where they compete for niches where their long-term survival is induced. In the absence of bone marrow homing, plasma cells are short-lived.
We have recently described a new plasma cell marker, CD93. This C-type lectin is expressed during the early stages of B cell development in the bone marrow and the spleen. We have shown that it is upregulated during plasma cell development (3). Its expression is maintained on long-lived plasma cells in the bone marrow niche. Little is know about the function of this molecule, nothing about its role in the plasma cell survival/homing. We were recently able to show that CD93 is required for retention of plasma cells in the bone marrow /4). In the absence of CD93 mice show a marked drop in long-term antibody production after immunization.
LATY136F mice show T cells with TH2 effector phenotype and function. They induce a hyper IgG1 and IgE syndrome when this linker cannot recruit PLCγ. When these effector T cells are mixed with naïve B cells in vitro they induce the same differentiation of B cells in an MHC and CD4-independent, cell-contact-dependent fashion. Amongst the co-stimulation molecules only CD80/86 but not ICOSL, CD40 are required for this effect. In vivo, in the absence of CD80/86 or CD28 the lymphoproliferation is not observed and CD40 KO mice make at later time points a hyper IgM and IgG1 syndrome (7).
Selected and recent publications
- Genton C, Wang Y, Izui S, Malissen B, Delsol G, Fournié GJ, Malissen M, Acha-Orbea H. The Th2 lymphoproliferation developing in LatY136F mutant mice triggers polyclonal B-cell activation and systemic autoimmunity. J Immunol. 2006 Aug 15;177(4):2285-93.
- Steiner QG, Otten LA, Hicks MJ, Kaya G, Sauberli E, Lavanchy C, Grosjean F, Beermann F, MacClain KL, Acha-Orbea H. In vivo Transformation of Mouse Conventional CD8alpha+ Dendritic Cells Leads to Progressive Multisystem Histiocytosis. Blood. 2008 Feb 15;111(4):2073-82. Epub 2007 Nov 20.
- Wang Y, Kissenpfennig A, Mingueneau M, Richelme S, Perrin P, Chevrier S, Genton C, Lucas B, DiSanto J, Acha-Orbea H, Malissen B, Malissen M. Th2 lymphoproliferative disorder of LatY136F mutant mice unfolds independently of TCR-MHC engagement and is insensitive to the action of Foxp3+ regulatory T cells. J Immunol. 2008 Feb 1;180(3):1565-75.
- Chevrier S, Genton C, Kallies A, Karnowski A, Otten L, Malissen B, Malissen M, Botto M, Corcoran LM, Nutt SL, Acha-Orbea H. CD93 is required for maintenance of antibody secretion and persistence of plasma cells in the bone marrow. Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3895-900. doi: 10.1073/pnas.0809736106. Epub 2009 Feb 19.
- Fuertes Marraco SA, Scott CL, Bouillet P, Ives A, Masina S, Vremec D, Jansen ES, O'Reilly LA, Schneider P, Fasel N, Shortman K, Strasser A, Acha-Orbea H. Type I interferon drives dendritic cell apoptosis via multiple BH3-only proteins following activation by PolyIC in vivo. PLoS One. 2011;6(6):e20189. doi: 10.1371/journal.pone.0020189. Epub 2011 Jun 2.
- Chevrier S, Genton C, Malissen B, Malissen M, Acha-Orbea H. Dominant Role of CD80-CD86 Over CD40 and ICOSL in the Massive Polyclonal B Cell Activation Mediated by LAT(Y136F) CD4(+) T Cells. Front Immunol. 2012;3:27. doi: 10.3389/fimmu.2012.00027. Epub 2012 Feb 24.
- Bär E, Gladiator A, Bastidas S, Roschitzki B, Acha-Orbea H, Oxenius A, LeibundGut-Landmann S. A novel Th cell epitope of Candida albicans mediates protection from fungal infection. J Immunol. 2012 Jun 1;188(11):5636-43. doi: 10.4049/jimmunol.1200594. Epub 2012 Apr 23.
- Cheng JM, Chee SH, Knight DA, Acha-Orbea H, Hermans IF, Timmer MS, Stocker BL. An improved synthesis of dansylated α-galactosylceramide and its use as a fluorescent probe for the monitoring of glycolipid uptake by cells. Carbohydr Res. 2011 May 15;346(7):914-26. doi: 10.1016/j.carres.2011.02.014. Epub 2011 Feb 19.
- Dunand-Sauthier I, Santiago-Raber ML, Capponi L, Vejnar CE, Schaad O, Irla M, Seguín-Estévez Q, Descombes P, Zdobnov EM, Acha-Orbea H, Reith W. Silencing of c-Fos expression by microRNA-155 is critical for dendritic cell maturation and function. Blood. 2011 Apr 28;117(17):4490-500. doi: 10.1182/blood-2010-09-308064. Epub 2011 Mar 8.
- Xu Y, Schnorrer P, Proietto A, Kowalski G, Febbraio MA, Acha-Orbea H, Dickins RA, Villadangos JA. IL-10 controls cystatin C synthesis and blood concentration in response to inflammation through regulation of IFN regulatory factor 8 expression. J Immunol. 2011 Mar 15;186(6):3666-73. doi: 10.4049/jimmunol.1001934. Epub 2011 Feb 7.
|Devika Ashok||Postdoctoral fellow|
|Driss Ehirchiou||Postdoctoral fellow|
|Sahar Ghassem Zadeh||MD/PhD student|
|Bhawna Gupta||Postdoctoral fellow|
|Sergio Haller||Ph.D student|
|Christoph Thelemann||Ph.D student|